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Purpose: To evaluate the efﬁ  cacy and safety of Neodymium:YAG (Nd:YAG) laser capsulotomy 
for posterior capsule opaciﬁ  cation (PCO) following combined phacoemulsiﬁ  cation and 
vitrectomy for the treatment of cataract in association with macular hole (MH) or epiretinal 
membrane (ERM).
Methods: Retrospective clinical study of 34 eyes of 34 patients who underwent combined 
cataract surgery and vitrectomy, developed PCO, and subsequently underwent Nd:YAG laser 
capsulotomy. Follow-up examinations included visual acuity measurement, evaluation of 
intraocular lens (IOL) centration, intraocular pressure (IOP) measurement, and dilated fundus 
examination.
Results: Nd:YAG laser capsulotomy was performed in all 34 eyes. The mean age of the patients 
was 65.08 years (range 45–87) and the mean follow up period was 11.05 months (range 4–23). 
The mean time elapsed between the last intraocular operation and the development of PCO was 
10.00 months for patients with previous ERM and 15.33 for those with MH (P = 0.001, t-test 
for equality of means). None of our patients developed recurrence of MH, retinal detachment, 
IOL dislocation, or permanent IOP elevation.
Conclusion: In our study, the most remarkable observation is that no complication occurred 
after the YAG capsulotomy, possibly because the eyes were vitrectomized and vitreous seems 
to play an important role in the occurrence of post-Nd:YAG complications. In addition we 
noted that PCO seems to occur earlier in the eyes undergoing combined surgery for cataract 
and ERM when compared with those where combined phacoemulsiﬁ  cation and vitrectomy are 
performed for cataract and MH.
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Introduction
Cataract, epiretinal membranes (ERM), and macular holes (MH) are distinct clinical 
entities frequently coexisting in the same patient.
Robert Machemer, who was the ﬁ  rst to establish an experimental model of retinal 
detachment, is best known for his development of pars plana vitrectomy for the 
treatment of vitreous hemorrhages in proliferative diabetic retinopathy.1 Nowadays, 
almost four decades since Machemer’s revolutionary work, performance of combined 
vitrectomy and phacoemulsiﬁ  cation is common when both cataract and vitreoretinal 
disease are present. This approach is necessary to enable adequate visualization of the 
posterior pole during vitreoretinal procedures and even if the opaque lens does not 
reduce visual function prior to surgery, it often progresses postoperatively as a result 
of vitreoretinal operation and the use of intraocular gas or silicone oil. Additionally, 
combined surgery has been considered to reduce intraoperative complication rates and 
allows immediate visual rehabilitation with only one operation.2–4Therapeutics and Clinical Risk Management 2009:5 134
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Posterior capsular opaciﬁ  cation (PCO) is the most common 
complication of cataract extraction, occurring in up to 33% 
of patients after ﬁ  ve years.5,6 PCO, apart from visual impair-
ment, can obscure fundus view and potentially compromise 
follow-up ability of patients with posterior segment pathology 
such as diabetic retinopathy and macular edema. Neodymium:
YAG (Nd:YAG) laser capsulotomy, the treatment of choice, 
is not without complications, some of which might be sight-
threatening such as macular edema and retinal detachment.7
Prognosis and complication rate of Nd:YAG laser capsu-
lotomy in patients having undergone combined vitreoretinal 
surgery and phacoemulsiﬁ  cation has been inadequately 
described in the literature.8–10 We reviewed a series of 34 eyes 
that developed PCO and required Nd:YAG laser capsulotomy 
after combined cataract and vitreoretinal surgery.
Patients and methods
We retrospectively reviewed the medical records of  34 patients 
(34 eyes) with PCO who had previously undergone combined 
pars plana vitrectomy with phacoemulsiﬁ  cation and intra-
ocular lens (IOL) implantation. All patients had surgery at 
the Department of Ophthalmology, Athens General Hospital 
‘G. Genimatas’ by a single surgeon.
All patients presented with decreased visual acuity which 
was attributed to PCO during their follow up in our clinic. 
Nd:YAG laser capsulotomy was performed if it was clini-
cally indicated by a decrease in visual acuity of two lines 
at least since previous examination or in the presence of a 
clinically opaque capsule. Nd:YAG laser capsulotomy was 
eventually performed in all 34 eyes. The procedure was 
performed under topical anesthesia (tetracaine drops), and 
pupil dilatation was achieved with the use of tropicamide 
1% and phenylephrine 10%. The procedure was interrupted 
if more than ﬁ  ve IOL pits were observed. Postoperative 
use of dexamethasone 0.1% and iopidine drops were 
prescribed for one week. Follow up examinations included 
visual acuity measurement, evaluation of IOL centration, 
intraocular pressure (IOP) measurement using Goldman 
applanation tonometry, and dilated fundus examination. 
The mean follow-up period (after Nd:YAG capsulotomy 
was performed) was 11 months.
Results
The demographic and clinical features of the patients are listed 
in Table 1. The mean age of the patients was 65.08 years (range 
45–87) and the mean follow up period was 11.05 months 
(range 4–23).
All eyes had clinically signiﬁ  cant lens opaciﬁ  cation at the 
time of vitreoretinal surgery. The indications for vitreoretinal 
surgery included: vitreomacular traction syndrome (VMT) 
(four eyes), MH (12 eyes) and the presence of an ERM (18 
eyes).
In all eyes after uncomplicated phacoemulsiﬁ  cation, 
the IOL (foldable three-piece hydrophobic acrylic PC IOL 
Acrysof MA60BM; Alcon Laboratories, Fort Worth, TX) 
with 5.5 mm optic diameter was implanted in the capsular 
bag through a 4.5 to 5 mm capsulorhexis. Subsequently 
in eyes with MH (12 eyes) and with VMT (4 eyes) a 
20-gauge-vitrectomy was performed with induction of PVD 
using the vitreous cutter to engage and pull on the peripapil-
lary vitreous. A volume of 0.3 ml of Trypan blue was injected 
in the vitreous cavity over the posterior pole and removed 
two minutes later; Internal limiting membrane (ILM) was 
peeled off from the macular area. Perﬂ  uoropropane C3F8 gas 
14% was used in the cases with MHs and the patient was 
instructed to adopt prone positioning for seven days. In eyes 
with ERMs, a 20-gauge-vitrectomy was performed, ERM 
peeling and subsequently the ILM was peeled of the macula 
with the aid of Trypan blue. No tamponade was used in any 
case with ERM or VMT.
Posterior capsule opacification was observed in all 
34 eyes and required an Nd:YAG capsulotomy because of 
deterioration in postoperative best-corrected visual acuity. 
None of the eyes had persistent endotamponade when they 
underwent Nd:YAG capsulotomy.
Postcapsulotomy, four eyes developed moderate 
anterior chamber reaction that resolved with topical cor-
ticosteroids. In seven eyes IOP increased temporarily for 
a few days post-op, but it was well controlled with topi-
cal antiglaucoma agents. None of our patients developed 
retinal detachment or recurrence of MH. IOL decentration 
or dislocation did not occur in any of the studied eyes. 
Cystoid macular edema was observed in two eyes that had 
undergone combined vitrectomy and phacoemulsiﬁ  cation 
for ERM removal, however, the edema was also evident 
before the YAG-capsulotomy and did not augment after 
the procedure.
The visual acuity pre- and post-YAG capsulotomy, as well 
as the time elapsed until the appearance of PCO are listed 
in Table 1 and vary according to the nature of the disease. 
It seems that PCO appears earlier (Table 2; P = 0.001, t-test 
for equality of means) in the eyes suffering an ERM (mean 
10.00 months) compared to patients with MH disease (mean 
15.33 months). No difference between the two groups was 
observed in age (P = 0.491, t-test for equality of means) or Therapeutics and Clinical Risk Management 2009:5 135
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in sex (P = 0.465, chi-square test). None of the eyes had any 
complication after the Nd:YAG capsulotomy.
Discussion
Posterior capsule opaciﬁ  cation remains the most common 
long-term complication after cataract surgery. It can be 
treated by Nd:YAG laser capsulotomy, however, this may 
lead to other complications. It has been suggested that 
PCO may be signiﬁ  cantly more extensive after combined 
vitrectomy and phacoemulsification than after cataract 
surgery alone.11 Toda and colleagues,11 in a study evaluating 
the degree of PCO in patients undergoing combined cataract 
and vitreoretinal surgery, concluded that the PCO rate was 
signiﬁ  cantly higher after combined surgery especially in 
patients with diabetes mellitus. After combined surgery eyes 
could also develop severe postoperative inﬂ  ammation, which 
probably leads to more extensive PCO.12,13 Lens epithelial 
cells (LECs) proliferate in response to many factors, one of 
which is inﬂ  ammation. It has been suggested that surgical 
trauma stimulates residual LECs to produce cytokines such 
Table 1 Data for patients treated with Nd:YAG capsulotomy
Case Age (yr) Sex Condition Follow-up (M) VA pre-YAG VA post-YAG
1 56 Male ERM 6 20/63 20/40
2 77 Male ERM 8 20/80 20/40
3 78 Female ERM 17 20/50 20/25
4 67 Female ERM 18 20/50 20/40
5 64 Female ERM 13 20/40 20/25
6 65 Female ERM 12 20/80 20/40
7 53 Male ERM 7 20/63 20/40
8 62 Female MH 7 20/100 20/63
9 54 Male MH 4 20/40 20/40
10 58 Male ERM 5 20/50 20/25
11 78 Male MH 19 20/100 20/63
12 83 Male VTS 15 20/60 20/40
13 45 Male ERM 8 20/40 20/25
14 56 Male MH 5 20/40 20/40
15 67 Male VTS 7 20/100 20/40
16 65 Male ERM 10 20/50 20/40
17 54 Male MH 14 20/32 20/25
18 87 Male MH 12 20/100 20/63
19 76 Male ERM 15 20/63 20/40
20 65 Female ERM 10 20/50 20/32
21 66 Male ERM 5 20/80 20/32
22 51 Female ERM 5 20/80 20/40
23 59 Female ERM 4 20/80 20/32
24 72 Female VTS 19 20/100 20/40
25 77 Female MH 21 20/40 20/32
26 69 Male ERM 23 20/63 20/40
27 61 Female MH 19 20/100 20/80
28 59 Male ERM 10 20/80 20/40
29 55 Female ERM 5 20/100 20/63
30 67 Female MH 18 20/40 20/32
31 78 Male MH 12 20/100 20/40
32 59 Male MH 8 20/63 20/40
33 51 Female MH 9 20/40 20/25
34 79 Female VTS 6 20/100 20/40
Abbreviations: ERM, epiretinal membrane; MH, macular hole;   VA, visual acuity; VTS, vitreomacular traction syndrome.
Note: Follow-up is measured in months, age is measured in years.Therapeutics and Clinical Risk Management 2009:5 136
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as interleukin-1 (IL-1), IL-6, IL-8, basic ﬁ  broblast growth 
factor and transforming growth factor. These cytokines may 
play an important role in ﬁ  brous proliferation of LECs via 
an autocrine pathway, paracrine pathway, or both.14,15 The 
degree of postoperative inﬂ  ammation appears to be related 
to PCO development after combined surgery even in patients 
without diabetes mellitus.11
Silicone IOLs have been considered to provoke PCO.16 
Other factors that are considered to contribute to the for-
mation of PCO include IOL decentration, capsulorhexis 
decentration, capsule tears, and insufﬁ  cient zonules, but in 
our cases we had none of these complications.
In our study, where we chose an acrylic IOL, the capsular 
ﬁ  brosis in the cases dealt with combined vitrectomy and 
phacoemulsiﬁ  cation was probably enhanced by accumulation 
of ﬁ  brin and proliferation of stimulating factors in the space 
between IOL and the posterior capsule. In cases treated with 
combined surgery the posterior capsule is “supported” by 
ﬂ  uid or gas and not from the vitreous, as it happens in eyes 
undergoing cataract surgery alone; this may have a role in 
the induction of posterior capsular ﬁ  brosis in the early post-
operative period, and this ﬁ  nding is in accordance with the 
f indings of other authors.17,18 Another contributing factor to 
early occurrence of PCO after combined surgery, could be the 
inﬂ  ammation which is induced by the prolonged surgery time 
and the combination of cataract with vitrectomy surgery.
In addition, the appearance of signiﬁ  cant PCO seemed 
to have occurred earlier in the eyes that underwent com-
bined surgery due to ERM (mean 10.0 months) compared 
to the patients having a MH preoperatively (15.33 months). 
Although it is difﬁ  cult to draw an accurate conclusion due 
to the small number of patients, it seems that the use of 
intravitreal gas which is used in all eyes undergoing MH 
surgery–but usually not in uncomplicated vitrectomy for 
ERM–does not enhance the occurrence of PCO. It is not 
unlikely that in cases with intravitreal gas use (MH cases), 
the gas “supports” the posterior capsule against the IOL and 
narrows the space between IOL and capsule forming a barrier 
to cell migration. On the other hand in cases with ERM the 
posterior capsule is loosely “supported” by the ﬂ  uid ﬁ  lling 
the vitreous cavity giving more space for cell migration 
between the IOL and the capsule. Additionally, the under-
lying condition responsible for the occurrence of the ERM 
such as branch retinal vein occlusion, uveitis, or previous 
cryotherapy or laser may have played an additional role in 
the earlier occurrence of PCO in eyes with ERMs.
Neodymium:YAG laser capsulotomy can cause short- 
and long-term IOP elevations that could possibly induce 
subsequent glaucoma and damage to the optic nerve.19 The 
underlying mechanism to this IOP rise after Nd:YAG laser 
capsulotomy remains unclear. Proposed mechanisms include 
effects to the ciliary body caused by the laser shock waves, 
a neurohumoral increase in the IOP, structural effects of laser 
energy on sodium hyaluronate, and ﬁ  nally mechanical block-
age of the trabeculum with various debris such as fragments 
from the disrupted posterior capsule or vitreous. Other well 
established complications of Nd:YAG laser capsulotomy are 
retinal detachment and macular edema.20,21 Proposed mecha-
nisms for the above complications include liquefaction of the 
vitreous and interruption of the anterior hyaloid face.
In our study, no major complication was observed after 
the YAG capsulotomy apart from transient mild IOP spikes 
that were easily controlled with antiglaucoma drops. The 
absence of complications of YAG laser in the vitrectomized 
eyes of our study could be attributed to the absence of vitre-
ous, alterations of which have been considered to play an 
important role in the development of IOP elevation, retinal 
detachment, and cystoid macular edema. Interestingly, IOL 
decentration or dislocation did not occur in any eye after 
YAG laser capsulotomy and the post-Nd:YAG capsulotomy 
visual acuity was restored in all 34 eyes.
Table 2 Table demonstrating the time elapsed between combined 
vitrectomy–phacoemulsiﬁ  cation and posterior capsule opaciﬁ  cation
Time until PCO
Case ERM MH
11 0 1 2
251 8
361 7
491 0
51 1 1 9
61 2 9
751 9
881 4
91 1 1 6
10 8 15
11 14 18
12 18 17
13 6
14 9
15 11
16 12
17 19
18 6
Abbreviations: ERM, epiretinal membrane; MH, macular hole; PCO, posterior 
capsule opaciﬁ  cation.
Note: Time until PCO is measured in months.Therapeutics and Clinical Risk Management 2009:5 137
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Conclusion
Nd:YAG capsulotomy seems to be a safe and effective procedure 
for eyes that have previously undergone combined phacoemul-
siﬁ  cation and vitrectomy surgery.
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